Thirty-two women with polycystic ovary syndrome (PCOS) were allocated to two antiandrogen treatment regimens; 28 women completed the trial. Twenty women were treated with ethinyloestradiol and cyproterone acetate (EO-CA) cyclically for 6 months and eight women were treated with the gonadotrophin releasing hormone (GnRH) analogue, goserelin for 6 months. Effects on hirsutism, insulin sensitivity (estimated by glucose clamp technique), blood lipids and hormones were measured. Women treated with EO-CA showed a reduction in hirsutism (P <0.05), and decreased serum androgen concentrations (P <0.001) as well as reduced insulin sensitivity (P <0.05). In women treated with goserelin, serum androgen concentrations also decreased (P <0.001), but there was no significant reduction of hirsutism. This group, however, showed an improved insulin sensitivity (P <0.05) despite an unchanged body mass index. Bone mineral density was unaltered in both treatment groups. The reduction in androgen concentrations caused by EO-CA was not paralleled by increased insulin sensitivity, most probably due to the effect of ethinyloestradiol per se. In contrast, the reduction in androgen concentrations by goserelin was accompanied by an improved insulin sensitivity.
Introduction
Women with the polycystic ovary syndrome (PCOS) show many features in common with a metabolic syndrome (Reaven, 1988) where the common denominator is insulin resistance. Fasting-and glucose-stimulated hyperinsulinaemia have been demonstrated in both lean and obese women with PCOS (Chang et al., 1983; Dunaif et al., 1987) . Positive correlations have been found between plasma insulin and serum testosterone in women with PCOS, indicating that hyperinsulinaemia contributes to the pathogenesis of the syndrome (Burghen et al., 1980; Shoupe and Lobo, 1984) . Impaired glucose tolerance or diabetes mellitus is present in up to 20% of women with PCOS (Dunaif et al., 1987; Dahlgren et al., 1992a) and they run a considerably increased risk of developing premature cardiovascular disease (Dahlgren et al., 1992b) . Since hyperandrogenicity is correlated with insulin resistance, we wanted to study how medication aimed at decreasing androgen production in women with PCOS affects insulin sensitivity. In addition, the effects on hirsutism, blood lipids, coagulation and fibrinolytic factors, as well as bone mineral density were studied. The androgenicity was depressed in three ways, namely by blocking the androgen receptors, by suppressing the ovarian steroid secretion, and by increasing the plasma concentration of sex hormone binding globulin (SHBG).
Materials and methods

Subjects
Thirty-two women aged 19-38 years, and diagnosed as having PCOS, attended the clinic of Obstetrics and Gynecology due to infertility or hirsutism problems. The diagnosis of PCOS was established by ovarian appearance on ultrasonography and with at least two out of three clinical symptoms typical of PCOS (oligomenorrhoea, obesity and hirsutism). Ovaries were defined as polycystic when eight follicles or more with diameters of ഛ10 mm, were located peripherally in the ovary around an enlarged, hyperechogenic stroma.
None of the women was diagnosed to have hypertension or diabetes mellitus before entering the study. Twenty-eight women completed the 6 months' antiandrogen treatment.
Assessment of hirsutism
It was assumed that therapeutic intervention had an impact on the rate of growth and the quality of coarse hair, rather than on the extent of hirsutism. Validating objective and subjective measurements of hirsutism have been made earlier (Azziz et al., 1995) . A subjective estimation of hirsutism was made as a simple score reflecting location, counting 1 point for each locus (face, trunk, arms, thighs) and up to 4 points for growth rate. For example, daily epilation was rated 4 points at each locus, every second day epilation was rated 3, once weekly epilation was rated 2, and once monthly epilation was rated 1 point. The hirsutism score was estimated before and during the last 2 weeks of the medical intervention.
Study protocol
Twenty women completed the 6 months' treatment with 50 mg of ethinyloestradiol and 100 mg of cyproterone acetate (Androcur; Schering, Berlin, Germany) (EO-CA). The treatment was applied in an inverse cycle originally described in 1969 (Hammerstein and Cupceancu, 1969) . Eight women completed treatment with the gonadotrophin releasing hormone (GnRH) analogue, goserelin (Zoladex; Zeneca, Manchester, UK), with 3.6 mg implanted s.c. every 28th day. The treatment was not a randomized choice but rather was dependent on the participants' individual need for medical treatment. Thus, women with problems predominantly of hirsutism were offered EO-CA treatment, while those with infertility problems were offered goserelin treatment, as part of a downregulation regimen prior to ovulation induction.
The duration of both types of medical intervention was 6 months. Clinical and laboratory investigations were performed before and during the last 2 weeks of treatment.
None of the participants had received any medication and all were without oral contraception or gestogens for 3 weeks before the study. The women were their own controls. The study was approved by the Ethics Committee of Sahlgrenska University Hospital. All women were provided with oral and written information about the study and gave their informed consent before participating.
Main outcome measure
The clinical effects of medical intervention on insulin sensitivity and lipid metabolism, coagulation and fibrinolytic factors, blood pressure, hirsutism, body composition and bone mineral density were studied.
Non-attendants
Four women began treatment with EO-CA but dropped out after between 1 and 5 months, two because of side effects (headache, heavy discharge), one because of surgery of a benign bone tumour, and one because of death in an accident. No data from the four nonattendants were included.
Clinical investigation
Data on reproductive and medical histories were collected and a general physical examination focusing on hirsutism was undertaken. A gynaecological examination was performed, including transvaginal ultrasonography of the uterus and ovaries using a 5 MHz probe (Toshiba, Nasuworks, Otawara-shi, Japan).
Anthropometry
Height and weight were measured with the women in underwear and without shoes. Height was measured to the nearest cm and weight to the nearest 100 g. The measurements were performed in the morning after an overnight fast. Body mass index (BMI) was calculated as bodyweight in kg divided by height in m 2 .
The waist-to-hip ratio (WHR), measured in a standing position with a soft tape, was calculated as the circumference in cm at the level of umbilicus divided by the greatest circumference at the level of the hips.
Total body potassium was determined in a whole-body counter detecting natural 40 K (Nuclear Enterprise, Edinburgh, UK) and expressed in mmol. Lean body mass was estimated according to the method of Forbes et al. (1961) in which 1 kg of lean body mass equals 68.1 mmol of potassium (lean body mass ϭ total body potassium/68.1). Body fat was calculated by subtracting the lean body mass from the bodyweight.
Blood pressure
Blood pressure was calculated as the mean of three measurements with a mercury sphygmomanometer on the right arm after 10 min in the supine position. Diastolic pressure was measured as Korotkoff phase V (when the sound disappears). A cuff size corresponding to the circumference of the right arm was chosen. With regard to smoking habits, women who smoked at least one cigarette a day were defined as smokers.
Bone mineral density measurements
Dual energy X-ray absorptiometry (Lunar DPX-L, Lunar Corp., Madison, WI, USA) was used to measure bone mineral density 2707 (BMD) in the total body, lumbar spine (L2-L4) and proximal femur (femoral neck, trochanter and Ward's triangle) as described previously (Mazess et al., 1990) . During the entire study period, a calibration phantom (Comac-BME Quantitative Assessment of Osteoporosis Study Group) was used. The coefficients of variation (CV) between the measurements were 0.4, 0.5 and 1.6% for total body BMD, lumbar spine L2-L4 and femoral neck, respectively.
Insulin sensitivity measurements
After an overnight fast, a hyperinsulinaemic, euglycaemic clamp examination was performed as previously described (De Fronzo et al., 1979) . Insulin and glucose were infused through a catheter inserted into an antecubital vein. Arterialized blood samples were collected after heating from a dorsal vein on the contralateral hand. Insulin (Actrapid, 100 IU/ml; Novo, Copenhagen, Denmark) was infused at a concentration of 500 mU/ml in isotonic saline, containing 2 ml of plasma from the subject to prevent losses of insulin.
A 20% glucose (1.1 M) solution was infused at varying rates in the same catheter as the insulin. A primed insulin infusion for 10 min was followed by a constant infusion of 0.12 U per kg bodyweight per min over a 120-min period. Blood was analysed for glucose concentration before and every 10 min during infusion. The rate of glucose infusion was adjusted to maintain a glucose level of 5.5 mmol/l. Samples for plasma insulin, C-peptide and free fatty acids (FFA) were taken before and after 80, 90, 100, 110 and 120 min of insulin infusion.
The glucose infusion rate during the clamp was assumed equal to the tissue glucose disposal rate during the last 30 min, when steady state was reached.
Blood sampling and analysis
Venous blood samples were withdrawn from an antecubital vein in the morning after an overnight fast. Blood glucose was analysed using a glucose oxidase method (Kabi, Stockholm, Sweden).
Insulin and C-peptide: Plasma insulin and C-peptide were determined with radioimmunoassay methods (Phadebas™; Pharmacia, Uppsala, Sweden and Byc-Sangtec; Ditzenbach, Germany, respectively).
Cholesterol and triglycerides: Serum cholesterol and triglycerides were determined enzymatically (Boehringer Mannheim, Germany).
Hormones: Venous blood samples were withdrawn from an antecubital vein after an overnight fast. Serum concentrations of oestradiol and thyroid stimulating hormone were determined by enzyme immunoassays using luminometry (Amerlite E2-60 and TSH-60; Amersham International plc, Amersham, UK). Sex hormone binding globulin (SHBG) was determined by an immunoradiometric assay (Farmos Group Ltd, Oulunsalo, Finland); serum testosterone by a non-extraction competitive radioimmunoassay using an antiserum against a T-19-carboxymethyl adduct to bovine serum albumin (Radioassay System Laboratories 125 IT; ICN Biochemicals Inc., Diagnostics Division, Costa Mesa, CA, USA). Free testosterone, androstenedione and DHEA-S were assayed by a competitive radioimmunoassay method using 125 I-labelled antibodies (Coat-A-Count®; Diagnostic Products Corporation-Skafte, Los Angeles, CA, USA).
Free thyroxine and serum triiodothyronine (T3) were assayed by radioimmunochemical assays.
Coagulation and fibrinolytic components: Blood was withdrawn for fibrinogen determination in 5-ml tubes containing 0.5 ml of 0.129 M trisodium citrate and 50 mg e-amino-caproic acid. The tubes were immediately centrifuged at 2000 g for 20 min at 4°C, after which the plasma was removed, divided into aliquots, snap frozen and stored at -70°C until analysed. Fibrinogen was analysed with a syneresis method (Nilsson and Olow, 1962) . Plasminogen activator inhibitor type 1 (PAI-1) activity was measured with an assay kit (Spectrolys pL; Biopool, Umeå, Sweden). Factor VII antigen (VII:Ag) was measured using an enzyme-linked immunosorbent assay (ELISA) (Stago, Asnières, France).
Statistical methods
Mean values and standard deviation (SD) were calculated using standard methods. Non-parametric tests (Mann-Whitney and Wilcoxon) were used for calculation of statistical intra-individual differences within each group.
Results
Clinical data
The clinical data of the two study groups are presented in Table I .
Effects of intervention with EO-CA
Data from these patients are listed in Table II. The hirsutism score was reduced after treatment with EO-CA for 6 months, and no differences were seen in anthropometric data.
Bone mineral density in the total body remained unchanged (1.22 Ϯ 0.10 and 1.21 Ϯ 0.10 g/cm 2 at the beginning and end of treatment, respectively). There was a reduction in glucose disposal rate when calculated per kg lean body mass (P Ͻ0.05) (Figure 1 ), but not when calculated per kg bodyweight (8.74 Ϯ 3.79 and 7.67 Ϯ 3.85 mg/kg bodyweight/min before and after treatment). Serum insulin and C-peptide increased (P Ͻ0.01), but the C-peptide:insulin ratio was unchanged, and fasting blood glucose was unaffected (4.7 Ϯ 0.4 versus 5.1 Ϯ 1.0 mmol/l). There was an almost 50% increase in serum triglycerides (P Ͻ0.05), and a 3-fold increase in SHBG (P Ͻ0.001). Free fatty acids were unchanged (0.67 Ϯ 0.26 versus 0.71 Ϯ 0.22 mmol/l), as was total cholesterol (5.00 Ϯ 0.99 versus 5.2 Ϯ 1.2 mmol/l).
Total and free testosterone (Figure 2 ) concentrations were reduced following treatment, as was the dihydroepiandrosterone (DHEAS) concentration, but androstenedione concentration was unchanged. The oestradiol concentration was reduced.
The mean concentration of serum T3 was increased by 40%, and there was an increase in Factor VII (P Ͻ0.05) while both PAI-1 activity (16.2 Ϯ 13.2 versus 11.8 Ϯ 16.5 U/ml) and plasma fibrinogen (3.17 Ϯ 0.73 versus 3.27 Ϯ 0.92 g/l) were unchanged.
Effects of intervention with GnRH analogue (goserelin)
Data from these patients are listed in Table III. There were no differences in anthropometric data after the treatment period and the hirsutism score was unchanged after treatment with goserelin for 6 months.
The bone mineral density was unaffected by goserelin (1.26 Ϯ 0.06 versus 1.24 Ϯ 0.07 g/cm 2 before and after treatment). An improved glucose disposal rate (Figure 1 ) was noted when calculated in relation to lean body mass (P Ͻ0.05), but this parameter was unchanged when calculated in relation to bodyweight (7.67 Ϯ 4.36 versus 8.31 Ϯ 4.35 mg/kg bodyweight/min). Blood glucose (4.95 Ϯ 1.01 versus 5.2 Ϯ 1.3 mmol/l), serum insulin and C-peptide were each unchanged by goserelin treatment, as was SHBG. Free fatty acids (0.77 Ϯ 0.22 versus 0.62 Ϯ 0.13 mmol/l) and total cholesterol (4.6 Ϯ 1.3 versus 5.0 Ϯ 0.9 mmol/l) were also both unchanged.
Total and free testosterone concentrations decreased (Figure 2) , as did serum concentrations of DHEA-S and androstenedione. Reduction also occurred in serum concentrations of both oestradiol and free thyroxine.
This patient group included one woman with acanthosis nigricans and severe insulin resistance. The inclusion of this patient in the goserelin group resulted in higher mean values for insulin (22.1 mU/l, compared with 12.1 mU/l in the EO-CA group). When this patient was excluded from the result, the mean insulin value of the goserelin group fell to 12.4 mU/l, though all other results were unaffected (data not shown).
Discussion
Antiandrogen has been the common treatment to reduce hirsutism in women with PCOS. The expected hormonal effect of the antiandrogenic treatment found in this study was a reduction of total and free serum testosterone as well as of DHEA-S in both treatment groups. Androstenedione was, however, only depressed in the GnRH-analogue-treated group. This type of hormonal response has been shown before (Azziz et al., 1995) . The decrease of hirsutism score was only evident in the EO-CA group, which might be due to a selection bias in this study population, with women in the EO-CA group showing a higher initial score and a longer duration of hirsutism. It has been shown earlier that GnRH analogues are effective for the treatment of hirsutism (Azziz et al., 1995; Carmino and Lobo, 1997) . Considering that many of the women with PCOS are insulinresistant, it is important to investigate how antiandrogen treatment affects their carbohydrate and lipid metabolism. Ovarian suppression with oral contraceptives combined with CA are often used to reduce hirsutism and to normalize irregular menstrual periods in women with PCOS. GnRHanalogues are commonly used for hormonal downregulation before in-vitro fertilization, in particular when hyperandrogenicity is present.
In the eight women treated with the GnRH-analogue, goserelin, there was an improved glucose disposal in peripheral tissues despite unchanged bodyweight. There were no changes in SHBG or serum insulin concentrations. The reason for an improved insulin sensitivity may be due to the reduction of serum androgens caused by goserelin. This finding, however, was not supported by earlier studies (Dunaif et al., 1990; Gadir et al., 1990; Lasco et al., 1995) . Further confirmation in extended studies is needed to establish the cause-effect relationship in women with hyperandrogenicity and insulin resistance.
In the EO-CA treatment group there was a decrease in glucose uptake in peripheral tissues, despite reduced free testosterone, unchanged bodyweight and increased SHBG. The serum concentration of insulin was also increased by the treatment of EO-CA, whereas fasting glucose concentrations were unaffected. The increased serum triglyceride concentrations found in the EO-CA group has been described earlier following doses of ethinyloestradiol as low as 10 µg (Lindberg et al., 1988) . Thus, EO-CA in this study showed a negative impact on carbohydrate and lipid metabolism which was unrelated to its antiandrogenic action. In addition, EO-CA increased Factor VII, which is another risk factor for cardiovascular disease (Meade et al., 1980) , but did not affect other factors such as plasma fibrinogen or PAI-1. There was no derangement of liver enzymes in this treatment group, indicating that there was no appreciable metabolic load on the liver (data not shown). The increase of T3 found in this study has been reported before in women on oral contraceptives and is 2710 due to increased thyroid-binding globulin induced by ethinyloestradiol.
When the women treated with EO-CA were subgrouped according to pretreatment insulin or WHR values there were no correlations found between high initial values and derangement of carbohydrate metabolism.
Treatment with oral contraceptives was reported to be associated with adverse effects on carbohydrate and lipid metabolism in normal women (Kasdorf and Kalkhoff, 1988; Goodsland et al., 1990; Watanabe et al., 1994) , as well as in women with PCOS (Korytkowski et al., 1995) . This treatment caused a reduced insulin sensitivity in peripheral tissue in women with or without a history of gestational diabetes (Skouby et al., 1987; Goodsland et al., 1992) .
Oral contraceptives are composed of ethinyloestradiol and 19-nor steroids, whereas CA is an antiandrogen component with a gestogen-like effect on the endometrium. In the present study an established regimen for treatment of hirsutism was chosen offering three different mechanisms of counteracting hyperandrogenism (Hammerstein and Cupceancu, 1969) . The metabolic effects of this medication were possibly very similar to the effects caused by ethinyloestradiol-containing oral contraceptives where the predominant effect on carbohydrate and lipid metabolism was exerted by ethinyloestradiol. The total body bone mineral density was unaltered in both treatment groups despite reduced serum concentrations of oestradiol and testosterone.
Untreated women with PCOS might run the increased risk of developing cardiovascular disease. Little is known about the long-term effects of different medical treatments of PCOS, two of which are illustrated in the present study. EO-CA therapy corresponds to oral contraceptive treatment. Our findings of changes in metabolic variables should encourage further searches for regimens with antiandrogenic properties, together with less adverse effects on metabolism.
Studies favouring the hypothesis of hyperinsulinism as the causative factor of hyperandrogenism show, for instance, that treatment of hyperandrogenic women with either bilateral oophorectomy, GnRH analogues or antiandrogens leads to reduced androgen levels without reducing hyperinsulinaemia (Geffner et al., 1986; Dunaif et al., 1990; Lasco et al., 1995) . In addition, Nestler et al. (1989) showed that treatment of hyperandrogenic women with diazoxide, an inhibitor of pancreatic insulin production, also reduced serum androgens and increased SHBG concentrations without changing gonadotrophin concentrations.
In contrast, there are also studies indicating that hyperandrogenism is the cause of hyperinsulinism: PCOS women treated with spironolactone showed reductions in serum androgen as well as insulin concentrations (Shoupe and Lobo, 1984) , and treatment with methyltestosterone resulted in glucose intolerance and insulin resistance treatment for female to male transsexuals (Polderman et al., 1994) and in leukaemic patients with aplastic anaemia (Woodart et al., 1981) .
Data from the present study might support the latter view on cause-effect relationship. However, the small amount of material obtained from the present study must be extended if this much debated problem is to be resolved.
In conclusion, EO-CA reduced hirsutism, decreased insulin sensitivity and increased triglycerides and coagulation Factor VII in PCOS. Goserelin improved insulin sensitivity, did not alter haemostatic variables or blood lipids, but had a minor effect on hirsutism. Blood pressure, bone mineral density and body composition were not affected by the antiandrogen treatment in PCOS in this study.
